MedPath

Tacrolimus Plus Glucocorticoid for Severe Thrombocytopenia in SS

Phase 2
Not yet recruiting
Conditions
Sjogren Syndrome With Other Organ Involvement
Interventions
Registration Number
NCT05694130
Lead Sponsor
Peking Union Medical College Hospital
Brief Summary

This 12-week randomized, open-label study evaluates the efficacy and safety of Tacrolimus combined with Glucocorticoid for Sjogren's syndrome patients with severe thrombocytopenia.

Detailed Description

This study evaluates the efficacy and safety of Tacrolimus combined with Glucocorticoid for the treatment of severe thrombocytopenia in Sjogren's syndrome patients.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
110
Inclusion Criteria
  • Diagnosis of Sjogren's syndrome according to the 2002 revised American-European Consensus Group (AECG) criteria.
  • Baseline platelet counts less than 30×109/L.
Exclusion Criteria
  • Concomitant other systemic autoimmune diseases.
  • Other severe complications of Sjogren's syndrome.
  • Abnormal laboratory tests such as: white blood cell count <2.5x10^9/L, hemoglobin <80 g/L, AST/ALT >1.5 ULN, serum creatine > 1.5 mg/dL.
  • Received glucocorticoids, immunosuppressants, or biological agents within 3 months.
  • Active acute or chronic infections.
  • History of malignancy.
  • Pregnancy or breastfeeding.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Prednisolone plus TacrolimusTacrolimusOral prednisolone 1mg/kg daily for 4 weeks, then tapered to 7.5mg in 8 weeks. Oral tacrolimus 1-2mg twice daily for 12 weeks.
Prednisolone monotherapyPrednisoloneOral prednisolone 1mg/kg daily for 4 weeks, then tapered to 7.5mg in 8 weeks.
Prednisolone plus TacrolimusPrednisoloneOral prednisolone 1mg/kg daily for 4 weeks, then tapered to 7.5mg in 8 weeks. Oral tacrolimus 1-2mg twice daily for 12 weeks.
Primary Outcome Measures
NameTimeMethod
Complete response rateweek 12

Complete response (platelet counts \> 100×10\^9/L) rates at week 12.

Secondary Outcome Measures
NameTimeMethod
Partial response rateweek 4, week 8 and week 12

Partial response (platelet counts 50-100×10\^9/L) rates at week 4, week 8 and week 12

ESSDAI improvementweek 12

Change from baseline in ESSDAI (EULAR Sjogren's Syndrome Disease Activity Index) score (0-123, higher is worse) at week 12.

ESSPRI improvementweek 12

Change from baseline in ESSPRI (EULAR Sjogren's Syndrome Patient Reported Index) score (0-10, higher is worse) at week 12.

Complete response rateweek 4 and week 8

Complete response (platelet counts \> 100×10\^9/L) rates at week 4 and week 8.

© Copyright 2025. All Rights Reserved by MedPath